Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Vanguard High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Vanguard High Dividend Yield ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Vanguard High Dividend Yield ETF trades at $166.3. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYVYM
Market Cap
$29.60B
Sector
Health
52-Week High
$491.22$166.14
52-Week Low
$205.48$136.63
Enterprise Value
$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Vanguard High Dividend Yield ETF

VYM trades at $166.67, up 0.37% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is highlighted in recent news for retirement income strategies, with a dividend of $0.98 scheduled for June 2026. It has shown strong performance, reaching new highs, though some articles note long-term underperformance versus the S&P 500.

The outlook is positive for income-focused investors due to its high-dividend yield and diversification, but risks include potential yield compression and market volatility. Analyst sentiment is mixed, with some advocating for its value exposure while others caution on growth limitations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Vanguard High Dividend Yield ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VYM